Method for treating parkinson's disease with a botulinum toxin
AssigneeAllergan Sales, Inc.
InventorStephen Donovan
Life of this patent
Estimating the term…
Abstract
Methods for treating a movement disorder by intracranial administration to a human patient of a therapeutically effective amount of a neurotoxin, such as a botulinum toxin type A.
Claims17
A method for temporary reduction of a dyskinesia of Parkinson's disease, the method comprising the step of intracranial administration of a botulinum toxin into a globus palladius or into a ventrolateral thalamus, thereby reducing a dyskinesia of Parkinson's disease.
A method for temporary reduction of a dyskinesia of Parkinson's disease, the method comprising the step of intracranial administration of a therapeutically effective amount of a botulinum toxin type A into the globus palladius or into the ventrolateral thalamus, thereby reducing a dyskinesia of Parkinson's disease.
A method for reducing a dyskinesia of Parkinson's disease, the method comprising the step of intracranial administration of a botulinum toxin into a globus palladius nucleus or into a ventrolateral thalamus nucleus of a patient, thereby reducing a dyskinesia of the patient for a period of time of between about 1 month and about 5 years.
A method for temporary reduction of a tremor of Parkinson's disease, the method comprising the step of intracranial administration of a botulinum toxin into a globus palladius or into a ventrolateral thalamus, thereby reducing a tremor of Parkinson's disease.
Dependencies are inferred from the claim text.